摘要
目的:探讨治疗前中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)对IIb^IVb期宫颈癌患者预后的预测价值。方法:回顾分析2013年9月至2014年12月于四川省肿瘤医院初次接受治疗的324例IIb^IVb期宫颈癌患者的临床病理资料。采用受试者工作特征曲线(ROC)分别确定NLR、PLR预测患者进展及生存的最佳临界值,根据最佳临界值分组,比较各组无进展生存期(PFS)及总生存期(OS)。采用单因素和COX多因素回归分析影响患者预后的因素。结果: NLR预测PFS、OS的临界值分别为3.01、3.04,PLR预测PFS、OS的临界值分别为206.06、217.05。单因素分析结果显示,FIGO分期、病理类型、肿瘤直径、淋巴结转移、治疗前NLR、治疗前PLR是影响中晚期宫颈癌患者PFS的预后因素,治疗前NLR、PLR是影响中晚期宫颈癌患者OS的预后因素。多因素分析结果显示,PLR为中晚期宫颈癌患者PFS及OS的独立预后因素。结论:高NLR与中晚期宫颈癌患者预后不良相关,PLR为中晚期宫颈癌患者进展与生存的独立预后因素。
Objective: To investigate the predictive value of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in the prognosis of patients with stage IIb^IVb cervical cancer before treatment. Methods: The clinical and pathological datas of 324 patients with stage IIb^IVb cervical cancer who were first treated in Sichuan Cancer Hospital from Sep.2013 to Dec.2014 were retrospectively reviewed.NLR and PLR cutoff optimisation for predicting the progression and survival of patients were performed using the standard ROC curve analysis.The progression-free survival and total survival time of each group were compared by grouping according to the optimal cut-off values.Univariate and multivariate regression analysis were used to analyze the prognostic factors. Results: The optimal cut-off values of NLR for predicting PFS and OS were 3.01 and 3.04 respectively,while those of PLR for predicting PFS and OS were 206.06 and 217.05 respectively.Univariate analysis:FIGO stage,histological type,tumor diameter,lymph node metastasis,pre-treatment NLR and PLR were prognostic factors of PFS in patients with advanced cervical cancer.Pre-treatment NLR and PLR were prognostic factors of OS in patients with advanced cervical cancer.Multivariate analysis:PLR was an independent prognostic factor for PFS and OS. Conclusion: High NLR is associated with poor prognosis in patients with advanced cervical cancer.PLR is an independent prognostic factor for progression and survival in patients with advanced cervical cancer.
作者
梅冰洁
张国楠
Mei Bingjie;Zhang Guonan(Department of Oncology,The Affiliated Hospital of Southwest Medical University,Luzhou 646000;Department of Gynecologic Oncology,Sichuan Cancer Hospital and Institute,The Affiliated Cancer Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041)
出处
《现代妇产科进展》
CSCD
北大核心
2019年第12期892-895,共4页
Progress in Obstetrics and Gynecology
